Alliance Global Partners analyst Ben Haynor downgraded Viveve Medical to Neutral from Buy and dropped coverage of the name after the company announced the pivotal PURSUIT trial in stress urinary incontinence in women did not meet its primary endpoint nor several secondary endpoints. The analyst expects little interest from potential acquirers and sees little upside for shareholders.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIVE: